Advancing patient safety in infusion therapy and vascular access

www.ivWatch.com
Meeting unmet patient safety needs with ingenuity, energy and experience.

At ivWatch, we believe that no patient should be harmed by intravenous (IV) therapy. Yet thousands suffer from the effects of IV failure each year.

Since the widespread adoption of IV therapy in the 1950s, visual and tactile inspections by nurses have remained the main lines of defense against sometimes serious and dangerous infiltrations and extravasations.

Continuous monitors exist to keep track of patients’ heart, blood oxygen levels and pulse rates. Yet no technology, until now, has been available to continuously monitor the health of a patient’s IV site, and whether drugs or fluids are actually being delivered through the vein.

Every infiltration and extravasation represents a drug dosing error. And these errors can also result in serious physical harm.

Meanwhile, health care facilities and providers are being held accountable for preventable hospital acquired infections (HAIs) and adverse drug events. At the same time, they must continue to improve patient safety and outcomes.

That’s why it’s our goal to improve the safety and effectiveness of IV therapy—and our first step is to provide a continuous monitoring solution that aids in the early detection of peripheral IV infiltration and extravasation events.

ivWatch is a medical device manufacturer focused on improving patient safety in infusion therapy and vascular access. With over a decade of science behind us, we’ve learned there are no shortcuts to success.

We follow a highly disciplined process of continuous research, development, refinement and testing. And we rely on collaboration with active clinicians and hospital-based testing.

An Experienced Team

The team at ivWatch brings together an extraordinary set of talent and expertise from diverse backgrounds. They are recognized vascular experts and leaders in the field of tissue optics, biomedical engineering, computational optical modeling and sensor design.

We are engineers and doctors. Inventors and technologists. Nurses and researchers. Teachers and scientists. And we are all united by a common mission: to eliminate patient harm associated with adverse events in IV therapy. That is our guiding purpose, and the reason we love the work we do.

Through our experienced leadership team and our partnerships within the medical industry, we are committed to transforming patient safety in vascular access and infusion therapy.
Introducing the ivWatch Model 400

This continuous monitoring device can quickly alert providers of possible IV infiltration and extravasation events.¹

The concept for the Model 400 originated in 1999, and the current device is the result of more than a decade of intensive development and clinical testing. The ivWatch Model 400 received FDA clearance in early 2015.

“EARLY DETECTION IS KEY TO IMPROVING PATIENT SAFETY. THE IVWATCH MODEL 400 DEVICE HAS HIGH SENSITIVITY¹ IN IDENTIFYING PERIPHERAL IV INFILTRATIONS.”

Jason Naramore
Chief Technology Officer
ivWatch

EARLY DETECTION IS KEY TO IMPROVING PATIENT SAFETY. THE IVWATCH MODEL 400 DEVICE HAS HIGH SENSITIVITY¹ IN IDENTIFYING PERIPHERAL IV INFILTRATIONS.”

Jason Naramore
Chief Technology Officer
ivWatch
“TO BE PART OF SOMETHING THAT WILL HELP SO MANY THOUSANDS OF PEOPLE IS A RARE AND AMAZING OPPORTUNITY. OUR HOPE IS THAT IVWATCH WILL BECOME AS UBIQUITOUS AS SEAT BELTS.”

Gary Warren
President and CEO, ivWatch, LLC